Vaccination against RSV: Is maternal vaccination a good alternative to other approaches?

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 6, 2013, Pages 1263-1267

  Kaaijk, Patricia ^a   Luytjes, Willem ^a   Rots, Nynke Y ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Immunology; Infant immunization; Maternal immunization; Risk groups; RSV; Seasonality; Vaccination strategy

Indexed keywords

GLYCOPROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN A; LIVE VACCINE; MATERNAL ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANTIGENIC VARIATION; CELLULAR IMMUNITY; HIGH RISK POPULATION; HUMAN; INFANT IMMUNIZATION; LOWER RESPIRATORY TRACT INFECTION; MATERNAL IMMUNIZATION; PRIMARY IMMUNE RESPONSE; REINFECTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RISK ASSESSMENT; SEASONAL VARIATION; TH1 TH2 BALANCE; VACCINATION; VACCINATION REACTION; VIRAL CLEARANCE;

IMMUNOLOGY; INFANT IMMUNIZATION; MATERNAL IMMUNIZATION; RISK GROUPS; RSV; SEASONALITY; VACCINATION STRATEGY;

FEMALE; HEALTH POLICY; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; PREGNANCY; PREGNANT WOMEN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; VACCINATION;

EID: 84880671035     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.24096     Document Type: Review

References (50)

1. Bueno SM, González PA, Cautivo KM, Mora JE, Leiva ED, Tobar HE, et al. Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG. Proc Natl Acad Sci U S A 2008; 105:20822-7; PMID:19075247; http://dx.doi.org/10.1073/pnas.0806244105.
2. Collins PL, Melero JA. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 2011; 162:80-99; PMID:21963675; http://dx.doi.org/10.1016/j.virusres.2011.09.020.
3. Resch B, Kurath S, Manzoni P. Epidemiology of respiratory syncytial virus infection in preterm infants. Open Microbiol J 2011; 5:135-43; PMID:22262986; http://dx.doi.org/10.2174/1874285801105010135.
4. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID:12517228; http://dx.doi.org/10.1001/ jama.289.2.179.
5. Groothuis JR, Hoopes JM, Jessie VG. Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention. Adv Ther 2011; 28:91-109; PMID:21318606; http://dx.doi.org/10.1007/ s12325-010-0100-z.
6. Sommer C, Resch B, Simões EA. Risk factors for severe respiratory syncytial virus lower respiratory tract infection. Open Microbiol J 2011; 5:144-54; PMID:22262987; http://dx.doi.org/10.2174/187428.5801105010144.
7. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 2012; 54:1427-36; PMID:22495079; http://dx.doi.org/10.1093/cid/cis211.
8. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360:588-98; PMID:19196675; http://dx.doi.org/10.1056/NEJMoa0804877.
9. Holman RC, Curns AT, Cheek JE, Bresee JS, Singleton RJ, Carver K, et al. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004; 114:e437-44; PMID:15466069; http://dx.doi.org/10.1542/peds.2004-0049.
10. Connors M, Collins PL, Firestone CY, Murphy BR. Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol 1991; 65:1634-7; PMID:1995956.
11. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, et al. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 1987; 61:3855-61; PMID:3316707.
12. Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol 1985; 66:2111-24; PMID:2413163; http://dx.doi.org/10.1099/0022-1317-66-10-2111.
13. Hendry RM, Burns JC, Walsh EE, Graham BS, Wright PF, Hemming VG, et al. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 1988; 157:640-7; PMID:3346563; http://dx.doi.org/10.1093/infdis/157.4.640.
14. Muelenaer PM, Henderson FW, Hemming VG, Walsh EE, Anderson LJ, Prince GA, et al. Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis 1991; 164:15-21; PMID:2056202; http://dx.doi.org/10.1093/infdis/164.1.15.
15. Sullender WM. Respiratory syncytial virus genetic and antigenic diversity. [table of contents.]. Clin Microbiol Rev 2000; 13:1-15; PMID:10627488; http://dx.doi.org/10.1128/CMR.13.1.1-15.2000.
16. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163:693-8; PMID:2010624; http://dx.doi.org/10.1093/infdis/163.4.693.
17. Piedra PA. Clinical experience with respiratory syncytial virus vaccines. Pediatr Infect Dis J 2003; 22(Suppl):S94-9; PMID:12671459; http://dx.doi.org/ 10.1097/01.inf.0000053893.15894.ff.
18. Ohuma EO, Okiro EA, Ochola R, Sande CJ, Cane PA, Medley GF, et al. The natural history of respiratory syncytial virus in a birth cohort: the influence of age and previous infection on reinfection and disease. Am J Epidemiol 2012; 176:794-802; PMID:23059788; http://dx.doi.org/10.1093/aje/kws257.
19. Mejías A, Ramilo O. Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics 2008; 2:433-9; PMID:19707374; http://dx.doi.org/10.2147/BTT. S3104.
20. Domachowske JB, Rosenberg HF. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. Clin Microbiol Rev 1999; 12:298-309; PMID:10194461.
21. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 2003; 21:3479-82; PMID:12850364; http://dx.doi.org/10.1016/ S0264-410X(03)00355-4.
22. Kruijsen D, Bakkers MJ, van Uden NO, Viveen MC, van der Sluis TC, Kimpen JL, et al. Serum antibodies critically affect virus-specific CD4+/CD8+ T cell balance during respiratory syncytial virus infections. J Immunol 2010; 185:6489-98; PMID:20971927; http://dx.doi.org/10.4049/jimmunol.1002645.
23. Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cellmediated immunity. J Pediatr 1980; 96:179-86; PMID:6243354; http://dx.doi.org/10.1016/ S0022-3476(80)80799-2.
24. Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory synctial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996; 70:2852-60; PMID:8627759.
25. Graham BS, Henderson GS, Tang YW, Lu X, Neuzil KM, Colley DG. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993; 151:2032-40; PMID:8345194.
26. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89:422-34; PMID:4305198.
27. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969; 89:405-21; PMID:4305197.
28. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, et al. The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 2007; 25:7372-8; PMID:17868959; http://dx.doi.org/10. 1016/j.vaccine.2007.08.014.
29. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012; 31:109-14; PMID:21926667; http://dx.doi.org/10.1097/INF.0b013e31823386f1.
30. Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G. Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children. Pediatr Infect Dis J 2009; 28:655-8; PMID:19483659; http://dx.doi.org/10.1097/INF. 0b013e318199c3b1.
31. Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, et al.; Purified Fusion Protein Vaccine Study Group. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 2003; 21:2448-60; PMID:12744878; http://dx.doi.org/10.1016/S0264-410X(03)00098-7.
32. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003; 21:3465-7; PMID:12850361; http://dx.doi.org/10.1016/S0264-410X(03)00352-9.
33. Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 2001; 184:1456-60; PMID:11709789; http://dx.doi.org/10.1086/324426.
34. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008; 198:1317-26; PMID:18855558; http://dx.doi.org/10.1086/592168.
35. Langley JM, Sales V, McGeer A, Guasparini R, Predy G, Meekison W, et al. A dose-ranging study of a subunit Respiratory Syncytial Virus subtype A vaccine with and without aluminum phosphate adjuvantation in adults > or =65 years of age. Vaccine 2009; 27:5913-9; PMID:19651171; http://dx.doi.org/10.1016/j. vaccine.2009.07.038.
36. Hurwitz JL. Respiratory syncytial virus vaccine development. Expert Rev Vaccines 2011; 10:1415-33; PMID:21988307; http://dx.doi.org/10.1586/erv.11.120.
37. Anderson R, Huang Y, Langley JM. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol 2010; 5:585-602; PMID:20353300; http://dx.doi.org/10.2217/fmb.10.22.
38. Widjojoatmodjo MN, Boes J, van Bers M, van Remmerden Y, Roholl PJ, Luytjes W. A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J 2010; 7:114; PMID:20525213; http://dx.doi.org/10.1186/1743-422X-7-114.
39. Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, et al. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 2003; 21:3647-52; PMID:12922094; http://dx.doi.org/10.1016/S0264- 410X(03)00426-2.
40. Teng MN, Whitehead SS, Bermingham A, St Claire M, Elkins WR, Murphy BR, et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000; 74:9317-21; PMID:10982380; http://dx.doi.org/10.1128/JVI.74.19.9317-9321.2000.
41. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981; 7:263-71; PMID:7038043; http://dx.doi.org/10.1002/jmv.1890070403.
42. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, Simoes EA. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009; 154:296-8; PMID:19150677; http://dx.doi.org/10.1016/j.jpeds.2008. 07.053.
43. Brandenburg AH, Groen J, van Steensel-Moll HA, Claas EC, Rothbarth PH, Neijens HJ, et al. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. J Med Virol 1997; 52:97-104; PMID:9131465; http://dx.doi.org/10.1002/(SICI)1096- 9071(199705)52:13.0.CO;2-Y.
44. Ochola R, Sande C, Fegan G, Scott PD, Medley GF, Cane PA, et al. The level and duration of RSVspecific maternal IgG in infants in Kilifi Kenya. PLoS One 2009; 4:e8088; PMID:19956576; http://dx.doi.org/10.1371/journal.pone. 0008088.
45. Shinoff JJ, O'Brien KL, Thumar B, Shaw JB, Reid R, Hua W, et al. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 2008; 198:1007-15; PMID:18702606; http://dx.doi.org/10.1086/591460.
46. Nandapalan N, Taylor CE, Greenwell J, Scott M, Scott R, Hey EN, et al. Seasonal variations in maternal serum and mammary immunity to RS virus. J Med Virol 1986; 20:79-87; PMID:3760842; http://dx.doi.org/10.1002/jmv.1890200110.
47. Le Saux N, Gaboury I, MacDonald N. Maternal respiratory syncytial virus antibody titers: season and children matter. Pediatr Infect Dis J 2003; 22:563-4; PMID:12828155; http://dx.doi.org/10.1097/01. inf.0000069796.72540.0a.
48. Moro PL, Broder K, Zheteyeva Y, Walton K, Rohan P, Sutherland A, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011; 204:146, e1-7; PMID:20965490; http://dx.doi.org/10.1016/j.ajog.2010.08.050.
49. Healy CM, Rench MA, Baker CJ. Implementation of cocooning against pertussis in a high-risk population. Clin Infect Dis 2011; 52:157-62; PMID:21288837; http://dx.doi.org/10.1093/cid/ciq001.
50. Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 2010; 32:1479-95; PMID:20728761; http://dx.doi.org/10.1016/j.clinthera.2010.07.017.